Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada

Reuters06-11

Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada

Sunshine Biopharma Inc.'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin®, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1038140) on June 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2542849395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542849395","market":"us","top_or_hot":-1,"title":"Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBFM\">Sunshine Biopharma Inc.</a>'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin®, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1038140) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBFM\">Sunshine Biopharma Inc.</a>'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin®, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1038140) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5CJDD3:1","article_id":"2542849395","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542849395","pubTimestamp":1749645037,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sunshine Biopharma Inc.'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SBFM":"Sunshine Biopharma Inc."},"translate_title":"Sunshine Biopharma子公司Nora Pharma Inc.在加拿大推出仿制药加巴喷丁","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SBFM":0.9},"content_text":"Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada\n    \n\nSunshine Biopharma Inc.'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin®, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1038140) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2542849395","isCrawlerRequest":true}